Table 1 Basic characteristics and treatment schedules in eligible studies
First author | Year | Design | Number of patients | Median age (range) | Irinotecan | Temozolomide | Days of each cycle | Line of therapy | Median number of cycles (range) | Total cycles of therapy |
|---|---|---|---|---|---|---|---|---|---|---|
Wagner | 2007 | Retrospective study | 16 | 18 (7–33) | 10–20 mg/m2/day on days 1–5 and days 8–12 | 100 mg/m2/day on days 1–5 | every 21–28 days | > = 2 | 5 (1–17) | 95 |
Anderson | 2008 | Retrospective study | 25 | 15 | 10 mg/m2/day on days 1–5 (or expand to 10 days) | 100 mg/m2/day on days 1–5 | NA | NA | 6 | NA |
Casey | 2009 | Retrospective study | 20 | 19.5 (2–40) | 10–20 mg/m2/day on days 1–5 and days 8–12 | 100 mg/m2/day on days 1–5 | every 21 days | > = 2 | 7.5 (1–20) | 154 |
Kurucu | 2015 | Retrospective study | 20 | 14 (1–18) | 20 mg/m2/day on days 1–5 and days 8–12 | 100 mg/m2/day on days 1–5 | every 28 days | > = 2 | 14 (7–18) | 97 |
Palmerini | 2018 | Retrospective study | 51 | 21 (3–65) | 40 mg/m2/day on days 1–5 | 100 mg/m2/day on days 1–5 | every 21 days | > = 1 | 5 (1–31) | NA |
Salah | 2021 | Retrospective study | 52 | 20 (5–45) | 40/50 mg/m2/day on days 1–5 or 20 mg/m2/day on days 1–5 and days 8–12 | 100 mg/m2/day on days 1–5 | every 21 days | > = 2 | 4 (1–7) | 236 |